BLUFFDALE, Utah, January 15, 2024 — Med 7, LLC (www.med7cbd.com) announces the recent granting of a US patent for Hempzorb81™, marking a significant milestone in health and wellbeing. This groundbreaking patent highlights Med 7® as the first Full Spectrum CBD product to receive such recognition for its efficacy in addressing overall health and wellbeing.
The comprehensive data within the patent underscores the transformative impact of Med 7® on reducing circulating levels of key indicators such as tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6). Impressively, regular consumption has been shown to decrease these markers by as much as 25 to 50% or more. Additionally, markers including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), have demonstrated reductions of up to 10 to 25% or more. The patent focuses specifically on patients with COVID-19 (SARS-CoV-2) with Med 7®, a full-spectrum hemp product made with Purzorb® technology, now trademarked as Hempzorb81™.
“We believe that the granting of this US patent for Med 7 is a testament to our shared dedication to advancing health and well-being and offering cutting-edge, non-pharmaceutical options.”
About Med 7
Med 7® is a technology-driven company that markets and distributes health and wellness products to medical professionals. Hempzorb81™ is a full spectrum hemp product made with Purzorb® technology, which mimics the body’s natural process of absorption by converting oil-based nutrients into water-soluble products. Hempzorb81™ is patent pending for other human health conditions.
For more information: Contact Med7, LLC: 801-577-4223, public.relations@med7usa.com, www.med7cbd.com
To view the complete patent: 11826320 (uspto.gov)
